Gu Juan J相关文献与解析，生知库 | 链接生命科学的每一步

Inhibition of USP1 reverses the chemotherapy resistance through destabilization of MAX in the relapsed/refractory B-cell lymphoma

抑制USP1可通过破坏MAX蛋白的稳定性逆转复发/难治性B细胞淋巴瘤的化疗耐药性。

Li, Xi-Ya; Wu, Ji-Chuan; Liu, Ping; Li, Zi-Juan; Wang, Yong; Chen, Bing-Yi; Hu, Cheng-Long; Fei, Ming-Yue; Yu, Peng-Cheng; Jiang, Yi-Lun; Xu, Chun-Hui; Chang, Bin-He; Chen, Xin-Chi; Zong, Li-Juan; Zhang, Jia-Ying; Fang, Ying; Sun, Xiao-Jian; Xue, Kai; Wang, Li; Chen, Shu-Bei; Jiang, Shi-Yu; Gui, Ai-Ling; Yang, Ling; Gu, Juan J; Yu, Bao-Hua; Zhang, Qun-Ling; Wang, Lan

B细胞

Evaluation safety and efficacy of immune checkpoint blockers (ICB) and radiotherapy combination versus ICB in non-small cell lung cancer patients with recurrence or metastasis: A systematic review and meta-analysis

评估免疫检查点抑制剂（ICB）联合放疗与单用ICB治疗复发或转移性非小细胞肺癌患者的安全性和有效性：系统评价和荟萃分析

期刊:Cancer Medicine

影响因子:3.1

doi:10.1002/cam4.5958

Zeng, Yichun; Zhang, Liying; Liang, Yichen; Zhang, Xian; Li, Lei; Wang, Maoqi; Guo, Jingliang; Li, Qiuxian; Cao, Jin; Gu, Juan J; Wang, Buhai

Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial

四个疗程的 R-CHOP 方案化疗后，根据中期 PET/CT 检查结果阴性，进行两次利妥昔单抗治疗：一项前瞻性试验的分析

期刊:BMC Cancer

影响因子:3.4

doi:10.1186/s12885-022-09486-4

Jin, Jia; Ji, Dongmei; Xia, Zuguang; Xue, Kai; Zhang, Qunling; Liu, Yizhen; Cao, Junning; Hong, Xiaonan; Gu, Juan J; Guo, Ye; Lv, Fangfang

Prevalence of Myositis-Specific Autoantibodies and Myositis-Associated Autoantibodies in COVID-19 Patients: A Pilot Study and Literature Review

COVID-19 患者中肌炎特异性自身抗体和肌炎相关自身抗体的患病率：一项初步研究和文献综述

期刊:Cureus Journal of Medical Science

影响因子:1.3

doi:10.7759/cureus.29752

Swartzman, Isaac; Gu, Juan J; Toner, Zachary; Grover, Raminder; Suresh, Lakshmanan; Ullman, Lori E

免疫/内分泌

发表日期：2022

文献求助收藏

Chidamide triggers BTG1-mediated autophagy and reverses the chemotherapy resistance in the relapsed/refractory B-cell lymphoma

西达米德可触发BTG1介导的自噬，并逆转复发/难治性B细胞淋巴瘤的化疗耐药性。

期刊:Cell Death & Disease

影响因子:9.6

doi:10.1038/s41419-021-04187-5

Xue, Kai; Wu, Ji-Chuan; Li, Xi-Ya; Li, Ran; Zhang, Qun-Ling; Chang, Jin-Jia; Liu, Yi-Zhen; Xu, Chun-Hui; Zhang, Jia-Ying; Sun, Xiao-Jian; Gu, Juan J; Guo, Wei-Jian; Wang, Lan

Determinants of COVID-19 Vaccine Response in Patients with Lymphoma on B Cell Directed Therapy

接受B细胞靶向治疗的淋巴瘤患者对COVID-19疫苗反应的决定因素

期刊:

影响因子:

doi:10.1182/blood-2021-152738

Ghodse, Hamid; Goel, Shipra; Gu, Juan J; Torka, Pallawi; Mavis, Cory; Sundaram, Suchitra; Neiders, Mirdza; Suresh, Lakshmanan; Shen, Long; Ramsperger, Vince; Griffiths, Elizabeth A; Segal, Brahm; Hernandez-Ilizaliturri, Francisco J; Ghione, Paola

The adhesion molecule ICAM-1 in diffuse large B-cell lymphoma post-rituximab era: relationship with prognostic importance and rituximab resistance.

利妥昔单抗治疗后弥漫性大B细胞淋巴瘤中粘附分子ICAM-1：与预后重要性和利妥昔单抗耐药性的关系

期刊:Aging-Us

影响因子:3.9

doi:10.18632/aging.202180

Liu Yizhen, Gu Juan J, Yang Ling, Tsai Ping-Chiao, Guo Ye, Xue Kai, Xia Zuguang, Liu Xiaojian, Lv Fangfang, Cao Junning, Hong Xiaonan, Mavis Cory, Hernandez-Ilizaliturri Francisco J, Zhang Qunling

细胞生物学

发表日期：2020

文献求助收藏

Development and Testing of an Intelligent Pain Management System (IPMS) on Mobile Phones Through a Randomized Trial Among Chinese Cancer Patients: A New Approach in Cancer Pain Management

通过对中国癌症患者进行随机试验，开发和测试基于移动电话的智能疼痛管理系统（IPMS）：癌症疼痛管理的新方法

期刊:Jmir Mhealth and Uhealth

影响因子:6.2

doi:10.2196/mhealth.7178

Sun, Yunheng; Jiang, Feng; Gu, Juan J; Wang, Y Ken; Hua, Hongwei; Li, Jing; Cheng, Zhijun; Liao, Zhijun; Huang, Qian; Hu, Weiwei; Ding, Gang

Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents

伏立诺他（Vorinostat）是一种组蛋白去乙酰化酶（HDAC）抑制剂，可促进细胞周期阻滞，并使对利妥昔单抗和化疗耐药的淋巴瘤细胞重新对化疗药物敏感。

期刊:Journal of Cancer Research and Clinical Oncology

影响因子:2.8

doi:10.1007/s00432-015-2026-y

Xue, Kai; Gu, Juan J; Zhang, Qunling; Mavis, Cory; Hernandez-Ilizaliturri, Francisco J; Czuczman, Myron S; Guo, Ye

Research trends of neoadjuvant therapy in lung cancer: a bibliometric analysis

肺癌新辅助治疗研究趋势：文献计量分析

Inhibition of USP1 reverses the chemotherapy resistance through destabilization of MAX in the relapsed/refractory B-cell lymphoma

抑制USP1可通过破坏MAX蛋白的稳定性逆转复发/难治性B细胞淋巴瘤的化疗耐药性。

Evaluation safety and efficacy of immune checkpoint blockers (ICB) and radiotherapy combination versus ICB in non-small cell lung cancer patients with recurrence or metastasis: A systematic review and meta-analysis

评估免疫检查点抑制剂（ICB）联合放疗与单用ICB治疗复发或转移性非小细胞肺癌患者的安全性和有效性：系统评价和荟萃分析

Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial

四个疗程的 R-CHOP 方案化疗后，根据中期 PET/CT 检查结果阴性，进行两次利妥昔单抗治疗：一项前瞻性试验的分析

Prevalence of Myositis-Specific Autoantibodies and Myositis-Associated Autoantibodies in COVID-19 Patients: A Pilot Study and Literature Review

COVID-19 患者中肌炎特异性自身抗体和肌炎相关自身抗体的患病率：一项初步研究和文献综述

Chidamide triggers BTG1-mediated autophagy and reverses the chemotherapy resistance in the relapsed/refractory B-cell lymphoma

西达米德可触发BTG1介导的自噬，并逆转复发/难治性B细胞淋巴瘤的化疗耐药性。

Determinants of COVID-19 Vaccine Response in Patients with Lymphoma on B Cell Directed Therapy

接受B细胞靶向治疗的淋巴瘤患者对COVID-19疫苗反应的决定因素

The adhesion molecule ICAM-1 in diffuse large B-cell lymphoma post-rituximab era: relationship with prognostic importance and rituximab resistance.

利妥昔单抗治疗后弥漫性大B细胞淋巴瘤中粘附分子ICAM-1：与预后重要性和利妥昔单抗耐药性的关系

Development and Testing of an Intelligent Pain Management System (IPMS) on Mobile Phones Through a Randomized Trial Among Chinese Cancer Patients: A New Approach in Cancer Pain Management

通过对中国癌症患者进行随机试验，开发和测试基于移动电话的智能疼痛管理系统（IPMS）：癌症疼痛管理的新方法

Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents

伏立诺他（Vorinostat）是一种组蛋白去乙酰化酶（HDAC）抑制剂，可促进细胞周期阻滞，并使对利妥昔单抗和化疗耐药的淋巴瘤细胞重新对化疗药物敏感。